Mesoblast Ltd - Asset Resilience Ratio

Latest as of June 2023: 0.00%

Mesoblast Ltd (MSB) has an Asset Resilience Ratio of 0.00% as of June 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Mesoblast Ltd debt and liabilities for a breakdown of total debt and financial obligations.

Liquid Assets

AU$-2.00K

≈ $-1.42K USD Cash + Short-term Investments

Total Assets

AU$669.41 Million

≈ $473.65 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2013–2023)

This chart shows how Mesoblast Ltd's Asset Resilience Ratio has changed over time. See MSB net asset value for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Mesoblast Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Mesoblast Ltd (MSB) total market value.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	AU$-2.00K	-0.0%
Short-term Investments	AU$0.00	0%
Total Liquid Assets	AU$-2.00K	0.00%

Asset Resilience Insights

Limited Liquidity: Mesoblast Ltd maintains only 0.00% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

Mesoblast Ltd Industry Peers by Asset Resilience Ratio

Compare Mesoblast Ltd's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Royalty Pharma Plc NASDAQ:RPRX	Biotechnology	0.10%
Ascendis Pharma AS NASDAQ:ASND	Biotechnology	0.00%
Biomarin Pharmaceutical Inc NASDAQ:BMRN	Biotechnology	3.28%
Shanghai RAAS Blood Products Co Ltd Class A SHE:002252	Biotechnology	4.52%
Ligand Pharmaceuticals Incorporated NASDAQ:LGND	Biotechnology	35.56%
Xiamen Amoytop Biotech Co Ltd SHG:688278	Biotechnology	4.69%
Neuren Pharmaceuticals Ltd AU:NEU	Biotechnology	90.43%
Jiangsu Aidea Pharmaceutical Co Ltd SHG:688488	Biotechnology	4.35%

Annual Asset Resilience Ratio for Mesoblast Ltd (2013–2023)

The table below shows the annual Asset Resilience Ratio data for Mesoblast Ltd.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2023-06-30	0.00%	AU$-2.00K ≈ $-1.42K	AU$669.41 Million ≈ $473.65 Million	0.00pp
2022-06-30	0.00%	AU$13.00K ≈ $9.20K	AU$662.14 Million ≈ $468.51 Million	+0.01pp
2021-06-30	-0.01%	AU$-49.00K ≈ $-34.67K	AU$744.72 Million ≈ $526.93 Million	-0.01pp
2020-06-30	0.00%	AU$12.00K ≈ $8.49K	AU$733.60 Million ≈ $519.07 Million	0.00pp
2019-06-30	0.00%	AU$21.00K ≈ $14.86K	AU$652.12 Million ≈ $461.41 Million	-0.05pp
2018-06-30	0.06%	AU$392.00K ≈ $277.36K	AU$692.44 Million ≈ $489.95 Million	-5.71pp
2017-06-30	5.76%	AU$37.79 Million ≈ $26.74 Million	AU$655.69 Million ≈ $463.94 Million	+5.40pp
2013-06-30	0.36%	AU$3.19 Million ≈ $2.26 Million	AU$883.71 Million ≈ $625.28 Million	--

pp = percentage points

About Mesoblast Ltd

AU:MSB Australia Biotechnology

Market Cap

$2.00 Billion

AU$2.82 Billion AUD

Market Cap Rank

#6270 Global

#144 in Australia

Share Price

AU$2.20

Change (1 day)

+0.00%

52-Week Range

AU$1.57 - AU$3.07

All Time High

AU$5.21